At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 232 enrolled
Drug / intervention
REL-1017 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating REL-1017 and Placebo for Major Depressive Disorder. Completed, enrolled 232 participants across 10 sites.
Detailed Summary
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedOct 2021
Primary CompletionSep 2022
Study CompletionSep 2022
TodayJul 2026
First PostedOct 18, 2021
Enrollment StartJun 2, 2021
Primary CompletionSep 13, 2022
Study CompletionSep 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.7 years ago
Interventions
REL-1017drug
REL-1017 tablet
Placebodrug
Placebo tablet